CN119823097A - Phd抑制剂化合物、组合物和用途 - Google Patents
Phd抑制剂化合物、组合物和用途 Download PDFInfo
- Publication number
- CN119823097A CN119823097A CN202510216379.8A CN202510216379A CN119823097A CN 119823097 A CN119823097 A CN 119823097A CN 202510216379 A CN202510216379 A CN 202510216379A CN 119823097 A CN119823097 A CN 119823097A
- Authority
- CN
- China
- Prior art keywords
- compound
- compound according
- formula
- alkyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062992585P | 2020-03-20 | 2020-03-20 | |
| US62/992,585 | 2020-03-20 | ||
| CN202180034124.XA CN115551845B (zh) | 2020-03-20 | 2021-03-19 | Phd抑制剂化合物、组合物和用途 |
| PCT/US2021/023219 WO2021188936A1 (en) | 2020-03-20 | 2021-03-19 | Phd inhibitor compounds, compositions, and use |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180034124.XA Division CN115551845B (zh) | 2020-03-20 | 2021-03-19 | Phd抑制剂化合物、组合物和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119823097A true CN119823097A (zh) | 2025-04-15 |
Family
ID=75639962
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510216379.8A Pending CN119823097A (zh) | 2020-03-20 | 2021-03-19 | Phd抑制剂化合物、组合物和用途 |
| CN202180034124.XA Active CN115551845B (zh) | 2020-03-20 | 2021-03-19 | Phd抑制剂化合物、组合物和用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180034124.XA Active CN115551845B (zh) | 2020-03-20 | 2021-03-19 | Phd抑制剂化合物、组合物和用途 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230227426A1 (https=) |
| EP (1) | EP4121425A1 (https=) |
| JP (2) | JP7768890B2 (https=) |
| KR (1) | KR20220156889A (https=) |
| CN (2) | CN119823097A (https=) |
| AR (1) | AR121618A1 (https=) |
| AU (1) | AU2021239378A1 (https=) |
| BR (1) | BR112022018877A2 (https=) |
| CA (1) | CA3176140A1 (https=) |
| CO (1) | CO2022014490A2 (https=) |
| IL (1) | IL296631A (https=) |
| MX (1) | MX2022011123A (https=) |
| TW (1) | TW202140443A (https=) |
| WO (1) | WO2021188936A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11713298B2 (en) | 2018-05-09 | 2023-08-01 | Akebia Therapeutics, Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
| WO2021117767A1 (ja) | 2019-12-10 | 2021-06-17 | 田辺三菱製薬株式会社 | 含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法 |
| CN115991698B (zh) * | 2022-11-03 | 2024-03-29 | 广东中科药物研究有限公司 | 一种杂环化合物及其制备方法与应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| DE102006050515A1 (de) * | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung |
| CA2894399A1 (en) | 2012-12-06 | 2014-06-12 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| EA031647B1 (ru) | 2013-03-29 | 2019-02-28 | Такеда Фармасьютикал Компани Лимитед | 6-(5-гидрокси-1h-пиразол-1-ил)никотинамидные ингибиторы phd |
-
2021
- 2021-03-19 AR ARP210100691A patent/AR121618A1/es unknown
- 2021-03-19 MX MX2022011123A patent/MX2022011123A/es unknown
- 2021-03-19 AU AU2021239378A patent/AU2021239378A1/en active Pending
- 2021-03-19 WO PCT/US2021/023219 patent/WO2021188936A1/en not_active Ceased
- 2021-03-19 TW TW110109982A patent/TW202140443A/zh unknown
- 2021-03-19 JP JP2022556170A patent/JP7768890B2/ja active Active
- 2021-03-19 CN CN202510216379.8A patent/CN119823097A/zh active Pending
- 2021-03-19 CA CA3176140A patent/CA3176140A1/en active Pending
- 2021-03-19 EP EP21720873.5A patent/EP4121425A1/en active Pending
- 2021-03-19 US US17/906,650 patent/US20230227426A1/en active Pending
- 2021-03-19 KR KR1020227036362A patent/KR20220156889A/ko active Pending
- 2021-03-19 IL IL296631A patent/IL296631A/en unknown
- 2021-03-19 CN CN202180034124.XA patent/CN115551845B/zh active Active
- 2021-03-19 BR BR112022018877A patent/BR112022018877A2/pt unknown
-
2022
- 2022-10-12 CO CONC2022/0014490A patent/CO2022014490A2/es unknown
-
2025
- 2025-10-30 JP JP2025183157A patent/JP2026021443A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022011123A (es) | 2023-01-04 |
| AU2021239378A1 (en) | 2022-11-17 |
| TW202140443A (zh) | 2021-11-01 |
| CN115551845A (zh) | 2022-12-30 |
| CA3176140A1 (en) | 2021-09-23 |
| US20230227426A1 (en) | 2023-07-20 |
| CO2022014490A2 (es) | 2022-10-21 |
| EP4121425A1 (en) | 2023-01-25 |
| JP2023518953A (ja) | 2023-05-09 |
| AR121618A1 (es) | 2022-06-22 |
| WO2021188936A1 (en) | 2021-09-23 |
| KR20220156889A (ko) | 2022-11-28 |
| CN115551845B (zh) | 2025-02-28 |
| JP7768890B2 (ja) | 2025-11-12 |
| JP2026021443A (ja) | 2026-02-10 |
| IL296631A (en) | 2022-11-01 |
| BR112022018877A2 (pt) | 2022-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115605467B (zh) | Phd抑制剂化合物、组合物和其用途 | |
| CN115551845B (zh) | Phd抑制剂化合物、组合物和用途 | |
| CN115515948B (zh) | Phd抑制剂化合物、组合物和用途 | |
| US20230295110A1 (en) | Phd inhibitor compounds, compositions, and methods of use | |
| US20240336568A1 (en) | Selective phd1 inhibitor compounds, compositions, and methods of use | |
| TWI917364B (zh) | Ｐｈｄ抑制劑化合物、組成物及使用方法 | |
| BR122025027331A2 (pt) | Compostos, composição farmacêutica e uso | |
| BR122025027329A2 (pt) | Compostos, composição farmacêutica e uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |